Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Rhea-AI Summary
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) held its virtual annual meeting of shareholders on September 19, 2024. Shareholders elected all nominated directors and approved the appointment of PricewaterhouseCoopers LLP as auditors. The election results showed strong support for all nominees, with approval rates ranging from 98.66% to 99.02%. The directors elected include Ken d'Entremont, Harmony Garges, Benoit Gravel, Michael Mueller, Stephen Nelson, Nancy Phelan, and Menassie Taddese. The appointment of auditors received 99.32% approval. A detailed report of the voting results will be filed with Canadian securities regulatory authorities and will be available on www.sedarplus.com.
Positive
- High shareholder approval rates for all director nominees (98.66% to 99.02%)
- Strong support for the appointment of PricewaterhouseCoopers LLP as auditors (99.32% approval)
Negative
- None.
News Market Reaction – MEDXF
On the day this news was published, MEDXF gained 0.27%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.
Detailed voting results for the election of directors are set out in the table below.
| Name | For | Against |
| Ken d'Entremont | ||
| Harmony Garges | ||
| Benoit Gravel | ||
| Michael Mueller | ||
| Stephen Nelson | ||
| Nancy Phelan | ||
| Menassie Taddese |
Shareholders also cast 8,922,492 (
A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.com.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Forward-Looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as "forward-looking information" or "forward-looking statements". The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on regulatory guidelines, historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that, although the assumptions are believed to be reasonable in the circumstances, these risks and uncertainties mean that actual results could differ, and could differ materially, from the expectations contemplated by the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223941
FAQ
When did Medexus Pharmaceuticals (MEDXF) hold its annual meeting of shareholders?
Who were elected as directors for Medexus Pharmaceuticals (MEDXF) in the 2024 annual meeting?
What was the approval rate for the appointment of auditors for Medexus Pharmaceuticals (MEDXF)?
Where can investors find the detailed voting results for Medexus Pharmaceuticals' (MEDXF) 2024 annual meeting?
